AstraZeneca earnings fall as generic drugs depress sales, 16% object to board pay
Updated : 10:39
Drug giant AstraZeneca popped the cap on falling first-quarter sales and earnings but both were at least in line with expectations, while shareholders later gave the board a 'bloody nose' on its director pay policy.